KMPH - KMPH STOCK NEWS

KemPharm, Inc. reported Q2 2022 results, revealing a net revenue of $1.3 million, significantly down from $12.0 million in Q2 2021. The company acquired arimoclomol from Orphazyme for $18.0 million to target Niemann-Pick disease type C. Despite a net loss of $24.0 million for Q2 2022, adjusted net loss was $6.4 million excluding one-time expenses. KemPharm has $114.5 million in cash, expected to fund operations beyond 2025. The company anticipates resubmitting the arimoclomol NDA in early 2023 and commencing a Phase 2 trial for KP1077 by year-end 2022.

KemPharm (NasdaqGS: KMPH) announced the appointment of Nichol Ochsner as Vice President, Investor Relations and Corporate Communications. In her new role, she will enhance external awareness of KemPharm’s value proposition, including relations with shareholders and analysts. Ms. Ochsner brings over 20 years of experience in investor relations within the biopharmaceutical sector. KemPharm is advancing its clinical pipeline with products like KP1077 and the FDA-approved AZSTARYS for ADHD, alongside a strong balance sheet.

KemPharm, a specialty pharmaceutical company focused on rare CNS and neurodegenerative diseases, announced a conference call on August 11, 2022, to discuss its Q2 2022 corporate and financial results. Investors can access the call via phone or through a live audio webcast available on the company's Investor Relations website. KemPharm's product portfolio includes arimoclomol for Niemann-Pick disease type C and KP1077 for idiopathic hypersomnia, alongside FDA-approved treatments like AZSTARYS and APADAZ. The conference aims to provide insights into the company’s performance and upcoming plans.

KemPharm, a specialty pharmaceutical company focused on rare CNS and neurodegenerative diseases, announced that Richard W. Pascoe will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 4:30 p.m. ET in Boston, MA. Management will also hold one-on-one meetings with attendees. The conference will feature insights on KemPharm's clinical-stage development pipeline, including treatments for Niemann-Pick disease and idiopathic hypersomnia, along with FDA-approved products like AZSTARYS and APADAZ.

KemPharm (NasdaqGS: KMPH) will attend the Niemann Pick Disease Foundation’s Family Support and Medical Conference and the International Niemann Pick Disease Association’s Biennial Meeting in Orlando, Florida, from July 28 to August 1, 2022. The company is committed to supporting the NPC advocacy community, as stated by Senior Vice President Christal Mickle. KemPharm focuses on developing treatments for rare CNS and neurodegenerative diseases, with a pipeline including arimoclomol for Niemann-Pick disease type C and KP1077 for idiopathic hypersomnia. FDA-approved products include AZSTARYS and APADAZ.

KemPharm, Inc. announced the publication of research highlighting serdexmethylphenidate (SDX) as a prodrug with significantly lower abuse potential compared to d-methylphenidate (d-MPH). Published in Current Medical Research & Opinion, the study involved three clinical trials demonstrating that SDX, as the active ingredient in KP1077 and AZSTARYS, yielded lower abuse-related effects and stimulant-like adverse events, classified as a Schedule IV controlled substance by the DEA. This differentiation positions KemPharm favorably in the CNS treatment market.

KemPharm announced a definitive agreement to acquire arimoclomol, an investigational drug for Niemann-Pick disease type C (NPC), from Orphazyme for USD $12.8 million. This acquisition aims to expand KemPharm's pipeline in rare CNS diseases and is expected to close on or before June 1, 2022. Arimoclomol is currently generating revenue through early access programs in the U.S., France, and Germany. The company plans to refile its New Drug Application by Q1 2023, following a previous Complete Response Letter from the FDA.

KemPharm reported Q1 2022 revenue of $4.0 million, a decline from $12.1 million in Q1 2021. The net loss for Q1 2022 was ($1.9 million), significantly improved from a loss of ($47.7 million) the prior year. The company filed an Investigational New Drug (IND) application with the FDA for KP1077, aimed at treating idiopathic hypersomnia, with a Phase 2 trial anticipated later in 2022. As of March 31, 2022, KemPharm had $119.1 million in cash and equivalents, expected to fund operations into 2025.

KemPharm, a specialty pharmaceutical company, announced management's participation in three investor conferences in May and June 2022. The events include the RBC Capital Markets Global Healthcare Conference on May 18, H.C. Wainwright Global Investment Conference on May 25, and the JMP Securities 2022 Life Sciences Conference on June 15. Each event will feature one-on-one meetings and live webcasts available on KemPharm's website. The company focuses on developing novel treatments for rare CNS diseases, utilizing its LAT® platform technology.